Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 USD | +3.96% | -1.87% | -52.27% |
Jul. 01 | Tempest Therapeutics, Inc.(NasdaqCM:TPST) added to Russell Microcap Growth Index | CI |
Jul. 01 | Tempest Therapeutics, Inc.(NasdaqCM:TPST) added to Russell 3000E Index | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 36.49 | 12.09 | 84.69 | 46.66 | - | - |
Enterprise Value (EV) 1 | 36.49 | 12.09 | 84.69 | 46.66 | 46.66 | 46.66 |
P/E ratio | - | -0.37 x | -2.3 x | -1.4 x | -1.31 x | -0.98 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -1.35 x | -0.35 x | -2.94 x | -1.31 x | -1.1 x | -0.92 x |
EV / FCF | - | - | -3.08 x | -1.49 x | -1.12 x | -0.73 x |
FCF Yield | - | - | -32.5% | -67.1% | -89.6% | -137% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 6,910 | 10,517 | 19,247 | 22,217 | - | - |
Reference price 2 | 5.280 | 1.150 | 4.400 | 2.100 | 2.100 | 2.100 |
Announcement Date | 3/29/22 | 3/22/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA 1 | - | -26.99 | -34.64 | -28.78 | -35.5 | -42.6 | -50.8 |
EBIT 1 | - | -26.99 | -34.64 | -29.16 | -33.09 | -42.16 | -58.06 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | -35.71 | -29.49 | -33.29 | -42.08 | -57.52 |
Net income 1 | -19.21 | - | -35.71 | -29.49 | -33.29 | -42.08 | -57.52 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | - | - | -3.090 | -1.910 | -1.496 | -1.603 | -2.136 |
Free Cash Flow 1 | - | - | - | -27.53 | -31.3 | -41.8 | -63.7 |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/13/21 | 3/29/22 | 3/22/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -7.338 | - | -8.662 | -8.771 | -8.934 | -7.581 | -7.387 | -6.504 | -7.429 | -7.886 | -8.3 | -8.7 | -10.6 | - | - |
EBIT 1 | -7.338 | -8.161 | -8.774 | -8.771 | -8.934 | -7.581 | -7.47 | -6.592 | -7.514 | -7.974 | -7.931 | -8.056 | -8.736 | -9.5 | -10.25 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | - | - | -9.103 | -7.636 | -7.581 | -6.786 | -7.488 | -7.904 | -8.004 | -8.259 | -9.026 | -9.875 | -10.75 |
Net income 1 | - | - | - | - | -9.103 | -7.636 | -7.581 | -6.786 | -7.488 | -7.904 | -8.004 | -8.259 | -9.026 | -9.875 | -10.75 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | - | - | - | - | -0.6300 | -0.5500 | -0.5400 | -0.4800 | -0.3400 | -0.3600 | -0.4040 | -0.3480 | -0.3580 | -0.4200 | -0.4600 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/29/22 | 5/13/22 | 8/15/22 | 11/8/22 | 3/22/23 | 5/10/23 | 8/10/23 | 11/8/23 | 3/19/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | -27.5 | -31.3 | -41.8 | -63.7 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | 0.17 | 0.2 | 0.65 | 0.9 |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 4/13/21 | 3/29/22 | 3/22/23 | 3/19/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.27% | 46.66M | |
+17.09% | 44.63B | |
+45.60% | 40.46B | |
-9.70% | 38.07B | |
+33.28% | 32.27B | |
-8.98% | 27.3B | |
+13.37% | 26.53B | |
+44.11% | 14.06B | |
+32.33% | 12.54B | |
-7.26% | 11.28B |
- Stock Market
- Equities
- TPST Stock
- Financials Tempest Therapeutics, Inc.